Last week we reported the FDA was developing its own artificial intelligence (AI) tool. Today (June 2) the agency gave it a name: Elsa.
Elsa is a large language model–powered AI tool designed to assist with reading, writing, and summarizing. It can summarize adverse events to support safety profile assessments, perform faster label comparisons and generate code to help develop databases for nonclinical applications, among its potential uses.
The agency gave no immediate explanation for the name.
Elsa is “a generative designed to help employees—from scientific reviewers to investigators—work more efficiently,” today’s announcement said. “This innovative tool modernizes agency functions and leverages AI capabilities to better serve the American people.”
Built within a high-security GovCloud environment, Elsa offers a secure platform for FDA employees to access internal documents while ensuring all information remains within the agency. The models do not train on data submitted by regulated industry, safeguarding the sensitive research and data handled by FDA staff.
The agency is already using Elsa to accelerate clinical protocol reviews, shorten the time needed for scientific evaluations, and identify high-priority inspection targets.
“Following a very successful pilot program with FDA’s scientific reviewers, I set an aggressive timeline to scale AI agency-wide by June 30, said FDA Commissioner Marty Makary. “Today’s rollout of Elsa is ahead of schedule and under budget, thanks to the collaboration of our in-house experts across the centers.”
Jeremy Walsh, recently appointed FDA’s first chief AI officer, added: “Today marks the dawn of the AI era at the FDA with the release of Elsa. AI is no longer a distant promise but a dynamic force enhancing and optimizing the performance and potential of every employee. As we learn how employees are using the tool, our development team will be able to add capabilities and grow with the needs of employees and the agency.”
The introduction of Elsa is the initial step in the FDA’s overall AI journey. As the tool matures, the agency has plans to integrate more AI in different processes, such as data processing and generative-AI functions to further support the FDA’s mission.
